Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hypersensitivity Reaction

  Free Subscription


Articles published in Eur J Dermatol

Retrieve available abstracts of 104 articles:
HTML format



Single Articles


    October 2024
  1. REYNAUD V, Dege T, Byrne N, Garcia-Piqueras P, et al
    Journal club: Biomarkers for atopic dermatitis: current use and perspectives.
    Eur J Dermatol. 2024;34:567-569.
    PubMed    


  2. FREITAS E, Yilmaz O, Torres T
    Effectiveness and tolerance of tralokinumab after failure with dupilumab and baricitinib in a patient with atopic dermatitis.
    Eur J Dermatol. 2024;34:551-553.
    PubMed    


  3. IKEZAWA S, Yokoyama E, Urakami H, Takigawa M, et al
    A case of anaphylaxis to kumquat (Citrus japonica).
    Eur J Dermatol. 2024;34:539-541.
    PubMed    


  4. HAGINO T, Onda M, Saeki H, Fujimoto E, et al
    Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan.
    Eur J Dermatol. 2024;34:525-532.
    PubMed     Abstract available


  5. METSINI A, Ryen L, Montgomery S, Svensson A, et al
    Healthcare visits, patterns of treatment, and related costs in children with controlled and uncontrolled atopic dermatitis in Sweden.
    Eur J Dermatol. 2024;34:509-516.
    PubMed     Abstract available


    August 2024
  6. NEUBAUER C, Kragl M, Braun T, Filipek P, et al
    An oil-in-water emulsion containing a combination of ginger extract and synthetic cannabidiol with potent in vitro anti-inflammatory effects alleviates symptoms of atopic dermatitis in a clinical trial.
    Eur J Dermatol. 2024;34:416-424.
    PubMed     Abstract available


  7. URENA-PANIEGO C, Sanabria-De-La-Torre R, Ramirez-Munoz A, Soto-Moreno A, et al
    Response to biological drugs and JAK inhibitors following cyclosporine in patients with atopic dermatitis.
    Eur J Dermatol. 2024;34:409-415.
    PubMed     Abstract available


  8. SOKOLOVSKIS A, Lapina L, Lauva A, Papirte S, et al
    Epidemiological and clinical characteristics of adult patients with chronic spontaneous urticaria in Latvia: insights from a two-centre study.
    Eur J Dermatol. 2024;34:398-408.
    PubMed     Abstract available


  9. GAMBICHLER T, Ardabili L, Domin B, Susok L, et al
    Predictors of disease severity, length of hospitalization, and recurrence in inpatients with single-organ cutaneous small vessel vasculitis.
    Eur J Dermatol. 2024;34:378-383.
    PubMed     Abstract available


  10. ZHOU X, Su J, Zhang CL, Dai H, et al
    Decreased expression of galectin-3 in the epidermis of psoriasis patients.
    Eur J Dermatol. 2024;34:371-377.
    PubMed     Abstract available


  11. BAKAR J, Michael-Jubeli R, Salmon M, Lancelot C, et al
    Effect of Th2 cytokines on ceramide subclasses based on a model of reconstructed human epidermis.
    Eur J Dermatol. 2024;34:361-370.
    PubMed     Abstract available


    June 2024
  12. GAMBICHLER T, Sandersfeld MH, Schaller J, Wiech T, et al
    Adult Henoch-Schonlein purpura complicated by IgA-nephritis in a patient with mantle cell lymphoma and Graves disease.
    Eur J Dermatol. 2024;34:318-320.
    PubMed    


  13. FOTI C, Calianno G, Sbarra G, Pisani MC, et al
    Crusted scabies diagnosed in an atopic patient during treatment with upadacitinib.
    Eur J Dermatol. 2024;34:311-312.
    PubMed    


  14. YOSHIDA S, Shiraishi K, Yatsuzuka K, Kohri N, et al
    Effects of hot bath therapy on cholinergic urticaria with hypohidrosis or anhidrosis.
    Eur J Dermatol. 2024;34:271-275.
    PubMed     Abstract available


    February 2024
  15. FUKUDA H, Aoki S, Harada Y, Matsumoto C, et al
    A case of acute generalized exanthematous pustulosis caused by eperisone hydrochloride.
    Eur J Dermatol. 2024;34:97-98.
    PubMed    


  16. OUNI B, Mansour K, Sassi M, Sriha B, et al
    Silodosin-induced leukocytoclastic vasculitis: a first case report.
    Eur J Dermatol. 2024;34:92-93.
    PubMed    


  17. GIMENEZ-ARNAU AM, Salman A, Podder I
    Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
    Eur J Dermatol. 2024;34:3-12.
    PubMed     Abstract available


    December 2023
  18. DE GREEF A, Ghislain PD, Baeck M
    Prolonged real-life experience with baricitinib in patients with moderate-to-severe atopic dermatitis.
    Eur J Dermatol. 2023;33:707-709.
    PubMed    


  19. NISHIYORI R, Sakai T, Nishida H, Hatano Y, et al
    An unusual case of immediate and delayed hypersensitivity to wasp stings.
    Eur J Dermatol. 2023;33:701-703.
    PubMed    


  20. TSAI YC, Tsai TF
    Successful treatment of atopic dermatitis by switching from upadacitinib to abrocitinib: a case report.
    Eur J Dermatol. 2023;33:699-701.
    PubMed    


  21. MIYAWAKI K, Nakashima C, Otsuka A
    Real-world effectiveness and safety of nemolizumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.
    Eur J Dermatol. 2023;33:691-692.
    PubMed    


  22. LAMOLET M, Barbarin C, Renaud O, Sahin Y, et al
    Acceleration of cutaneous T-cell lymphoma mistaken for atopic dermatitis following JAK inhibitor use.
    Eur J Dermatol. 2023;33:686-687.
    PubMed    


  23. COHEN E, Lheure C, Ingen-Housz-Oro S, Hotz C, et al
    Which first-line treatment for cutaneous sarcoidosis? A retrospective study of 120 patients.
    Eur J Dermatol. 2023;33:680-685.
    PubMed     Abstract available


    October 2023
  24. MURRAY C, Ridge K, Conlon N
    Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria.
    Eur J Dermatol. 2023;33:561-562.
    PubMed    


  25. NISHITANI K, Nakajima S, Miyake T, Kaku Y, et al
    Cutaneous sarcoidosis concomitant with xanthoma on the face.
    Eur J Dermatol. 2023;33:559-561.
    PubMed    


  26. KAMADA H, Arakawa N, Fukui R, Tanji T, et al
    Nemolizumab-induced drug eruption in a 46-year-old male patient with atopic dermatitis.
    Eur J Dermatol. 2023;33:558-559.
    PubMed    


  27. FIGUEIREDO C, Matos AL, Cardoso JC
    Bilateral periorbital swelling as the presenting manifestation of recurrent breast carcinoma.
    Eur J Dermatol. 2023;33:551-553.
    PubMed    


  28. ZHENG H, Chen Y, Xu Y, Deng X, et al
    Efficacy and safety of abrocitinib for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis: update of a living systematic review and meta-analysis.
    Eur J Dermatol. 2023;33:530-543.
    PubMed     Abstract available


  29. LUGER T, Chu CY, Elgendy A, Ibrahim SBBK, et al
    Pimecrolimus 1% cream for mild-to-moderate atopic dermatitis: a systematic review and meta-analysis with a focus on children and sensitive skin areas.
    Eur J Dermatol. 2023;33:474-486.
    PubMed     Abstract available


    August 2023
  30. YAMADA M, Furuta M, Fujimoto N
    Erythema multiforme major induced by tramadol.
    Eur J Dermatol. 2023;33:437-439.
    PubMed    


  31. TOYOSHIMA M, Nakaoji K, Hamada K, Yamanaka A, et al
    Analysis of skin aging patterns using a facial imaging system in patients with atopic dermatitis.
    Eur J Dermatol. 2023;33:383-393.
    PubMed     Abstract available


  32. ESCALANTE A, Serra-Baldrich E
    Pathogenic mechanisms underlying itch in atopic dermatitis: the emerging role of neuroimmune interactions.
    Eur J Dermatol. 2023;33:343-349.
    PubMed     Abstract available


  33. YU YY, Li JX, Zeng YP
    Scientific landscape and trend analysis of chronic urticaria: a two-decade bibliometric review.
    Eur J Dermatol. 2023;33:404-412.
    PubMed     Abstract available


  34. UOZUMI T, Serizawa N, Hagino T, Morita T, et al
    Dietary habits in Japanese patients with bullous pemphigoid: low intake of retinol.
    Eur J Dermatol. 2023;33:394-403.
    PubMed     Abstract available


    April 2023
  35. KOMAKI R, Miyagaki T, Okano T, Takeuchi S, et al
    Decreased serum placental growth factor levels in adult atopic dermatitis: a preliminary study.
    Eur J Dermatol. 2023;33:185-186.
    PubMed    


  36. MATOS PR, Nogueira A, Gomes N, Pedrosa A, et al
    Acute generalized exanthematous pustulosis secondary to mianserin with liver involvement.
    Eur J Dermatol. 2023;33:172-174.
    PubMed    


  37. DEYDIER N, Salvado M, Planes M, Misery L, et al
    Atopic dermatitis in 15q24 microdeletion syndrome: a social media study.
    Eur J Dermatol. 2023;33:157-159.
    PubMed     Abstract available


  38. PATSATSI A, Vakirlis E, Kanelleas A, Stefanaki I, et al
    Effect of a novel "emollient plus" formulation on mild-to-severe atopic dermatitis and other dry skin-related diseases as monotherapy or adjunctive therapy: an observational study on efficacy, tolerance and quality of life in adult patients.
    Eur J Dermatol. 2023;33:137-146.
    PubMed     Abstract available


  39. LI JX, Zeng YP
    Research interest in the usage of dupilumab for atopic dermatitis: a bibliometric analysis.
    Eur J Dermatol. 2023;33:87-100.
    PubMed     Abstract available


    February 2023
  40. MOSNIER A, Vocanson M, Lefevre MA
    Molecular profiling of skin test-induced inflammation to support the clinical diagnosis of delayed drug hypersensitivity reaction.
    Eur J Dermatol. 2023;33:64-66.
    PubMed    


  41. LAMOUROUX C, Bertolotti-Potachin L, Charbotel B, Nosbaum A, et al
    Allergic contact dermatitis to diclofenac gel due to propylene glycol sensitization: usefulness of repeated open application tests to determine safer alternatives.
    Eur J Dermatol. 2023;33:42-43.
    PubMed    


    November 2022
  42. ELDANI C, Darrigade AS, Beylot-Barry M, Jullie ML, et al
    Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as "toxic epidermal necrolysis-like".
    Eur J Dermatol. 2022;32:805-807.
    PubMed    


  43. KOSAKA K, Uchiyama A, Ishikawa M, Watanabe G, et al
    Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-centre retrospective study.
    Eur J Dermatol. 2022;32:800-802.
    PubMed    


  44. KIM J, Choi S, Choi S, Lee YI, et al
    Contact hypersensitivity and Demodex mite infestation in patients with rosacea: a retrospective cohort analysis.
    Eur J Dermatol. 2022;32:716-723.
    PubMed     Abstract available


  45. SALOMON G, Giordano-Labadie F
    Surfactant irritations and allergies.
    Eur J Dermatol. 2022;32:677-681.
    PubMed     Abstract available


    September 2022
  46. HONDA R, Suenaga A, Nakahara T, Shibata-Kikuchi S, et al
    Atopic dermatitis refractory to dupilumab but markedly responsive to baricitinib.
    Eur J Dermatol. 2022;32:649-650.
    PubMed    


  47. STEFANOU G, Gregoriou S, Kontodimas S, Sfaelos K, et al
    Prevalence of adult self-reported atopic dermatitis in Greece: results from a nationwide survey.
    Eur J Dermatol. 2022;32:597-606.
    PubMed     Abstract available


  48. MELE-NINOT G, Serra-Baldrich E, Spertino J, Guilarte M, et al
    Are antihistamines still used during omalizumab treatment for chronic spontaneous urticaria?
    Eur J Dermatol. 2022;32:629-631.
    PubMed     Abstract available


  49. SALONEN J, Remitz A, Salonen J, Lauerma A, et al
    Allergic conjunctivitis: a risk factor for recurrent herpes simplex virus infections in patients with atopic dermatitis.
    Eur J Dermatol. 2022;32:607-614.
    PubMed     Abstract available


  50. TIOTIU A, Jaussaud R
    Successful treatment with omalizumab for cold urticaria in a patient with chronic hepatitis C virus infection.
    Eur J Dermatol. 2022;32:640-641.
    PubMed    


  51. TETART F, Gonde H, Hervouet C
    Do generic drugs cause hypersensitivity?
    Eur J Dermatol. 2022;32:571-576.
    PubMed     Abstract available


    July 2022
  52. PIOTIN A, Hacard F, Crumbach L, Nicolas JF, et al
    Anaphylaxis to chlorhexidine after taking oral medication
    Eur J Dermatol. 2022;32:551-553.
    PubMed    


  53. BRAUN C, Patra V, Lina G, Nicolas JF, et al
    The role of skin dysbiosis in atopic dermatitis
    Eur J Dermatol. 2022;32:439-444.
    PubMed     Abstract available


  54. WOLLENBERG A, Lio P, Kleyn E, Bissonnette R, et al
    Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials
    Eur J Dermatol. 2022;32:522-529.
    PubMed     Abstract available


  55. SERRANO ORDONEZ A, Lopez Riquelme I, Perea Polak A
    sQuiz your knowledge! Persistent unilateral facial and lip swelling
    Eur J Dermatol. 2022;32:562-563.
    PubMed    


  56. KITAYAMA S, Makino T, Kataoka K, Mori S, et al
    Valacyclovir-induced drug reaction with eosinophilia and systemic symptoms
    Eur J Dermatol. 2022;32:538-539.
    PubMed    


  57. MARTINEZ-SAGUER I, Dominas N, Straben U, Greve J, et al
    Patients with hereditary angioedema and their treatment patterns in Germany: a Delphi consensus study
    Eur J Dermatol. 2022;32:487-494.
    PubMed     Abstract available


  58. PANKAKOSKI A, Kluger N, Sintonen H, Panelius J, et al
    Clinical manifestations and comorbidities of pemphigus: a retrospective case-control study in southern Finland
    Eur J Dermatol. 2022;32:480-486.
    PubMed     Abstract available


    May 2022
  59. LEFEVRE MA
    "Prick or treat": a case of systemic reaction during intradermal tests with beta-lactams
    Eur J Dermatol. 2022;32:426-428.
    PubMed    


  60. FUJISHIMA C, Munemoto S, Hioki C, Sasaki H, et al
    Successful dupilumab therapy for atopic dermatitis in a patient with X-linked agammaglobulinaemia
    Eur J Dermatol. 2022;32:416-417.
    PubMed    


  61. NAKAGAWA M, Hanada M, Amano H
    Allergic contact stomatitis caused by (meth)acrylates following sensitization by artificial nails, 20 years previously
    Eur J Dermatol. 2022;32:413-415.
    PubMed    


  62. ROLO DE MATOS P, Nogueira A, Gomes N, Costa C, et al
    Rare presentation of Wells syndrome mimicking angioedema: a case report
    Eur J Dermatol. 2022;32:411-413.
    PubMed    


  63. ULDAHL A, Sterner T, Bruze M, Dahlin J, et al
    Atopy patch testing and associations with atopic conditions and specific IgE tests: a population-based study in adolescents
    Eur J Dermatol. 2022;32:384-393.
    PubMed     Abstract available


  64. GUILLON C, Meziani M, Abdelli S, Sigaudo Roussel D, et al
    The aryl hydrocarbon receptor pathway plays a central role in the cutaneous response to pollutants
    Eur J Dermatol. 2022;32:305-311.
    PubMed     Abstract available


    April 2022
  65. SCHUSTER B, Ziehfreund S, Schielein MC, Tizek L, et al
    Adding happiness to complement the Dermatology Quality of Life Index in psoriasis and atopic dermatitis healthcare: a cross-sectional study
    Eur J Dermatol. 2022;32:220-226.
    PubMed     Abstract available


  66. MASUDA K, Delozier AM, Kolodsick J, Buchanan A, et al
    Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysi
    Eur J Dermatol. 2022;32:237-243.
    PubMed     Abstract available


  67. STEFANIAK AA, Knecht K, Matusiak L
    sQuiz your knowledge! Non-pruritic chronic urticaria and recurrent episodes of fever
    Eur J Dermatol. 2022;32:300-301.
    PubMed    


    February 2022
  68. VAN HALEWIJN KF, Lahnstein T, Bohnen AM, Van Den Berg PJ, et al
    Recommendations for emollients, bathing and topical corticosteroids for the treatment of atopic dermatitis: a systematic review of guidelines.
    Eur J Dermatol. 2022 Feb 21. pii: ejd.2022.4197. doi: 10.1684/ejd.2022.4197.
    PubMed     Abstract available


  69. NADA HR, Rashed LA, Shehada J, Mostafa PIN, et al
    Phosphodiesterase 4 (PDE4) gene expression in atopic dermatitis patients, before and after treatment with topical mometasone cream.
    Eur J Dermatol. 2022 Feb 15. pii: ejd.2022.4194. doi: 10.1684/ejd.2022.4194.
    PubMed     Abstract available


  70. ESCURE G, Nudel M, Terriou L, Farhat MM, et al
    Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.
    Eur J Dermatol. 2022;32:49-55.
    PubMed    


    January 2022
  71. LEFEVRE MA, Mosnier A
    A case of paracetamol-induced nonpigmented fixed drug eruption confirmed by a lymphocyte transformation test.
    Eur J Dermatol. 2022;32:154-156.
    PubMed    


  72. SHEN X, Zhang W, Li X, Lu H, et al
    Association between serum IgG and Henoch-Schonlein purpura with renal involvement in children: a cross-sectional study.
    Eur J Dermatol. 2022;32:132-134.
    PubMed    


    December 2021
  73. SALAVA A, Perala M, Juppo M, Pelkonen AS, et al
    Effective treatment of atopic dermatitis in small children significantly improves the quality of life of patients and their families.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4169. doi: 10.1684/ejd.2021.4169.
    PubMed     Abstract available


  74. EGEBERG A, Anderson P, Piercy J, Massey L, et al
    Symptom burden of patients with moderate-to-severe atopic dermatitis.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4166. doi: 10.1684/ejd.2021.4166.
    PubMed     Abstract available


  75. LORET L, Ninclaus V, Dendooven A, Lapeere H, et al
    Canalicular stenosis associated with dupilumab treatment for atopic dermatitis.
    Eur J Dermatol. 2021 Dec 17. pii: ejd.2021.4180. doi: 10.1684/ejd.2021.4180.
    PubMed    


  76. CHESTER J, Kaleci S, Liberati S, Alicandro T, et al
    Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis.
    Eur J Dermatol. 2021 Dec 15. pii: ejd.2021.4168. doi: 10.1684/ejd.2021.4168.
    PubMed     Abstract available


  77. LEFEVRE MA, Mohme S, Alband N, Nogueira M, et al
    Journal club: New small molecules for atopic dermatitis management.
    Eur J Dermatol. 2021;31:849-852.
    PubMed    


  78. TRAIDL S, Heratizadeh A, Werfel T, Dressler C, et al
    Online survey to identify current challenges in atopic dermatitis management and guideline implementation in German-speaking countries.
    Eur J Dermatol. 2021;31:806-812.
    PubMed     Abstract available


  79. ROVATI C, Rossi M, Gelmetti A, Tomasi C, et al
    Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients.
    Eur J Dermatol. 2021;31:736-740.
    PubMed     Abstract available


  80. RAVAL NS, Snowden CK, De Monnin KS, Yokoyama CC, et al
    Scarring alopecia developing after mogamulizumab-associated rash.
    Eur J Dermatol. 2021;31:841-843.
    PubMed    


  81. SUKAKUL T, Svedman C, Dahlin J, Bergendorff O, et al
    Simultaneous positive patch test reactions to neomycin and low-molecular-weight heparins: possible cross-reaction?
    Eur J Dermatol. 2021;31:741-743.
    PubMed     Abstract available


    October 2021
  82. KURIHARA K, Fujiyama T, Tokura Y, Honda T, et al
    Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
    Eur J Dermatol. 2021 Oct 26. pii: ejd.2021.4140. doi: 10.1684/ejd.2021.4140.
    PubMed    


  83. KHELLAF L, Cosserat J, Calas A, Brasme H, et al
    Unusual neurological and cardiac complications of drug reaction with eosinophilia and systemic symptoms syndrome: a case report.
    Eur J Dermatol. 2021;31:652-654.
    PubMed    


  84. FANG YH, Wei KC, Yu MS
    Improvement of erythema elevatum diutinum refractory to dapsone following treatment for underlying multiple myeloma.
    Eur J Dermatol. 2021;31:655-657.
    PubMed    


    August 2021
  85. INGEN-HOUSZ-ORO S, Staumont-Salle D, Palladini A, Ferries L, et al
    Immunosuppressants as steroid-sparing agents for chronic DRESS: four cases.
    Eur J Dermatol. 2021;31:576-577.
    PubMed    


    June 2021
  86. LEFEVRE MA, Nosbaum A
    Dermpath and Clinic: How to manage adverse reactions to biological agents.
    Eur J Dermatol. 2021;31:426-427.
    PubMed    


  87. CUI Y, Shi J, Wang C, Vinturache A, et al
    Therapeutic plasma exchange combined with continuous venovenous hemofiltration in a series of pediatric patients with toxic epidermal necrolysis.
    Eur J Dermatol. 2021;31:413-415.
    PubMed    


  88. WATABE D, Amano H
    TNF-alpha inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis.
    Eur J Dermatol. 2021;31:412-413.
    PubMed    


  89. PERRON E, Viarnaud A, Marciano L, Karkouche R, et al
    Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms.
    Eur J Dermatol. 2021;31:372-380.
    PubMed     Abstract available


  90. SUGINO H, Nakamura M
    Mild hypertrichosis in both upper arms around dupilumab injection sites.
    Eur J Dermatol. 2021;31:420-421.
    PubMed    


    April 2021
  91. MORIMOTO H, Fukuchi K, Ogura Y, Ohtsuka M, et al
    Development of lichen planus following benralizumab treatment.
    Eur J Dermatol. 2021 Apr 2. pii: ejd.2021.3995. doi: 10.1684/ejd.2021.3995.
    PubMed    


  92. GIORDANO-LABADIE F, Becherel PA, Pralong P, Outtas O, et al
    Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Eur J Dermatol. 2021;31:217-224.
    PubMed     Abstract available


    March 2021
  93. KIRSTEN N, Mohr N, Maul JT, Augustin M, et al
    Incidence of atopic conditions in people with psoriasis: a population-based analysis.
    Eur J Dermatol. 2021 Mar 1. pii: ejd.2021.3963. doi: 10.1684/ejd.2021.3963.
    PubMed     Abstract available


    February 2021
  94. BELBEZIER A, Boccon-Gibod I, Bouillet L
    Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Eur J Dermatol. 2021;31:86-87.
    PubMed    


  95. KOMATSU-FUJII T, Ogawa M, Nonoyama S, Fukumoto T, et al
    Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1(R)) after nivolumab discontinuation.
    Eur J Dermatol. 2021;31:98-99.
    PubMed    


  96. KUMANO Y, Nagai A, Sugiura K
    Erythro-papular type drug eruption caused by fosravuconazole L-lysine ethanolate.
    Eur J Dermatol. 2021;31:90-91.
    PubMed    


  97. UGAJIN T, Namiki T, Yokozeki H
    A case of prurigo caused by hair dye containing p-phenylenediamine: histopathological findings.
    Eur J Dermatol. 2021;31:103-104.
    PubMed    


  98. MAKIHARA-INUKAI M, Takeichi T, Ogawa-Momohara M, Muro Y, et al
    Morphea in a Crohn's disease patient undergoing ustekinumab treatment.
    Eur J Dermatol. 2021;31:96-97.
    PubMed    


  99. FAUCON C, Bernigaud C, Sbidian E, Hue S, et al
    Essential oils as potential triggers for bullous pemphigoid? A report of two patients.
    Eur J Dermatol. 2021;31:92-93.
    PubMed    


  100. HAYAMA K, Fujita H, Asai-Sato M, Kawana K, et al
    Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
    Eur J Dermatol. 2021;31:100-101.
    PubMed    


    January 2021
  101. NAGASAWA Y, Iinuma S, Fujii M, Kanno K, et al
    Dasatinib-induced panniculitis in a patient with chronic myeloid leukaemia.
    Eur J Dermatol. 2021 Jan 25. pii: ejd.2020.3946. doi: 10.1684/ejd.2020.3946.
    PubMed    


  102. COSTEDOAT I, Vergara R, Dousset L, Gerard E, et al
    Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod.
    Eur J Dermatol. 2021 Jan 15. pii: ejd.2020.3951. doi: 10.1684/ejd.2020.3951.
    PubMed    


    December 2020
  103. DANSET M, Hacard F, Jaulent C, Nosbaum A, et al
    Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Eur J Dermatol. 2020 Dec 18. pii: ejd.2020.3910. doi: 10.1684/ejd.2020.3910.
    PubMed    


    November 2020
  104. KIMURA R, Sugita K, Yamamoto O
    Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Eur J Dermatol. 2020 Nov 24. pii: ejd.2020.3904. doi: 10.1684/ejd.2020.3904.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Hypersensitivity Reaction is free of charge.